Status:
UNKNOWN
Use of Pharmacogenetics in the Treatment of Children With Autistic Spectrum Disorders
Lead Sponsor:
Assaf-Harofeh Medical Center
Conditions:
Autism
Neuroleptic Treatment
Eligibility:
All Genders
3-18 years
Brief Summary
Children with autism are often treated with psychiatric drugs. These medications have been shown to improve their language and social function, and are important in improving their quality of life. In...
Eligibility Criteria
Inclusion
- Age\> 3 years
- Diagnosed with autism
- Treated with neuroleptics
Exclusion
- Patients with known allergy to second generation neuroleptics.
- Patients with moderate to severe renal insufficiency
- Patients with liver disease
- Patients with active cardiac disease
- Patients with hypertension not responsive to anti-hypertensive therapy
- Patients with substance abuse
- Suicidal patients
Key Trial Info
Start Date :
March 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2011
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT00859664
Start Date
March 1 2009
End Date
July 1 2011
Last Update
March 11 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assaf Harofeh Medical center
Ẕerifin, Israel, 70300